- Home
- ELS vs NBIX Comparison
ELS vs NBIX Comparison
Compare ELS & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELS | NBIX |
|---|---|---|
| Founded | 1992 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7B | 13.2B |
| IPO Year | 1993 | 1996 |
Fundamental Metrics
Financial Performance| Metric | ELS | NBIX |
|---|---|---|
| Price | $62.63 | $137.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 21 |
| Target Price | $69.94 | ★ $176.24 |
| AVG Volume (30 Days) | ★ 1.6M | 1.1M |
| Earning Date | 01-28-2026 | 02-11-2026 |
| Dividend Yield | ★ 3.33% | N/A |
| EPS Growth | 1.89 | ★ 12.44 |
| EPS | 1.99 | ★ 4.19 |
| Revenue | $1,531,382,000.00 | ★ $2,682,700,000.00 |
| Revenue This Year | $1.08 | $23.55 |
| Revenue Next Year | $4.26 | $19.18 |
| P/E Ratio | ★ $31.05 | $32.13 |
| Revenue Growth | N/A | ★ 19.61 |
| 52 Week Low | $58.15 | $84.23 |
| 52 Week High | $70.35 | $160.18 |
Technical Indicators
Market Signals| Indicator | ELS | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 53.89 | 48.52 |
| Support Level | $62.52 | $132.75 |
| Resistance Level | $64.35 | $138.74 |
| Average True Range (ATR) | 1.19 | 3.36 |
| MACD | 0.08 | 0.55 |
| Stochastic Oscillator | 58.05 | 86.35 |
Price Performance
Historical ComparisonAbout ELS Equity Lifestyle Properties Inc.
Equity Lifestyle Properties is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently has a portfolio of 455 properties across the US with a higher concentration in the Sunbelt region with 38% of the company's properties located in Florida, 12% in Arizona, and 8% in California. Equity Lifestyle targets owning properties in attractive retirement destinations with over 70% of the company's properties either being age-restricted or having an average resident age over 55.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.